Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
4.9
$ 20.00
In stock
(338)
Product Description
Overall Survival with Palbociclib and Fulvestrant in Advanced
Evolution of overall survival and receipt of new therapies by
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast
Ribociclib Plus Fulvestrant Continued to Improve OS in Advanced
Modeling the novel SERD elacestrant in cultured fulvestrant
Updated overall survival from the MONALEESA-3 trial in
Overall Survival Results with KISQALI® (ribociclib)
2021 Update on Systemic Therapy for Breast Cancer
CDKI Plus Fulvestrant Confers Overall Survival Benefit in Advanced
Cost Effectiveness of Ribociclib in Combination with Fulvestrant
Overall Survival with Ribociclib plus Fulvestrant in Advanced
Health-related quality of life in premenopausal women with hormone
Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive
Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive
